Using immune cells to deliver drugs to inflamed tissues
Adoptive Macrophage Transfers for Nanoparticle Delivery
['FUNDING_OTHER'] · UNIVERSITY OF COLORADO · NIH-10862738
This study is exploring how special immune cells called macrophages can help deliver tiny particles filled with medicine directly to areas in the body that are inflamed, which could improve treatment for conditions like cancer, autoimmune diseases, and heart problems.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO (nih funded) |
| Locations | 1 site (Boulder, UNITED STATES) |
| Trial ID | NIH-10862738 on ClinicalTrials.gov |
What this research studies
This research investigates how immune cells, specifically macrophages, can be used to transport nanoparticles that carry drugs and other therapeutic agents directly to inflamed tissues. By understanding how different properties of these nanoparticles affect the behavior of macrophages, researchers aim to enhance the effectiveness of drug delivery for conditions like cancer, autoimmune diseases, and cardiovascular diseases. The study involves creating various types of nanoparticles and observing how they interact with macrophages to optimize their delivery capabilities.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from inflammatory conditions such as cancer, autoimmune diseases, or cardiovascular diseases.
Not a fit: Patients with non-inflammatory conditions or those who do not respond to immune-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more targeted and effective treatments for patients with inflammatory diseases.
How similar studies have performed: Previous research has shown promise in using immune cells for targeted drug delivery, indicating that this approach has potential for success.
Where this research is happening
Boulder, UNITED STATES
- UNIVERSITY OF COLORADO — Boulder, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHIELDS IV, CHARLES WYATT — UNIVERSITY OF COLORADO
- Study coordinator: SHIELDS IV, CHARLES WYATT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, Cancers, Cardiovascular Diseases, Communicable Diseases